These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30236179)

  • 1. A systematic review of clinical outcomes on the WHO Category II retreatment regimen for tuberculosis.
    Cohen DB; Meghji J; Squire SB
    Int J Tuberc Lung Dis; 2018 Oct; 22(10):1127-1134. PubMed ID: 30236179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P; Chitsaz E; Tabatabaei V; Baghaei P; Shamaei M; Farnia P; Marjani M; Kazempour M; Mansouri D; Masjedi MR; Velayati AA
    Am J Ther; 2011 Sep; 18(5):343-9. PubMed ID: 20535008
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area.
    Schreiber YS; Herrera AF; Wilson D; Wallengren K; Draper R; Muller J; Dawood H; Doucette S; Cameron DW; Alvarez GG
    Int J Tuberc Lung Dis; 2009 Oct; 13(10):1274-80. PubMed ID: 19793433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of relapse and failure after retreatment with the Category II regimen in Nepal.
    Yoshiyama T; Shrestha B; Maharjan B
    Int J Tuberc Lung Dis; 2010 Nov; 14(11):1418-23. PubMed ID: 20937181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A case series: initial outcome of persons with multidrug-resistant tuberculosis after treatment with the WHO standard retreatment regimen in Ho Chi Minh City, Vietnam.
    Lan NTN ; Lademarco MF; Binkin NJ; Tung LB; Quy HT; Cĵ NV
    Int J Tuberc Lung Dis; 2001 Jun; 5(6):575-8. PubMed ID: 11409587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
    Espinal MA; Kim SJ; Suarez PG; Kam KM; Khomenko AG; Migliori GB; Baéz J; Kochi A; Dye C; Raviglione MC
    JAMA; 2000 May; 283(19):2537-45. PubMed ID: 10815117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study.
    Jones-López EC; Ayakaka I; Levin J; Reilly N; Mumbowa F; Dryden-Peterson S; Nyakoojo G; Fennelly K; Temple B; Nakubulwa S; Joloba ML; Okwera A; Eisenach KD; McNerney R; Elliott AM; Ellner JJ; Smith PG; Mugerwa RD
    PLoS Med; 2011 Mar; 8(3):e1000427. PubMed ID: 21423586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of Category II anti-tuberculosis treatment in Indian children.
    Mukherjee A; Khandelwal D; Singla M; Lodha R; Kabra SK
    Int J Tuberc Lung Dis; 2015 Oct; 19(10):1153-7. PubMed ID: 26459525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line anti-tuberculosis drug resistance patterns and trends at the national TB referral center in Iran--eight years of surveillance.
    Shamaei M; Marjani M; Chitsaz E; Kazempour M; Esmaeili M; Farnia P; Tabarsi P; Amiri MV; Mirsaeidi M; Mansouri D; Masjedi MR; Velayati AA
    Int J Infect Dis; 2009 Sep; 13(5):e236-40. PubMed ID: 19285897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retreatment tuberculosis cases. Factors associated with drug resistance and adverse outcomes.
    Kritski AL; Rodrigues de Jesus LS; Andrade MK; Werneck-Barroso E; Vieira MA; Haffner A; Riley LW
    Chest; 1997 May; 111(5):1162-7. PubMed ID: 9149564
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isoniazid-monoresistant tuberculosis is associated with poor treatment outcomes in Durban, South Africa.
    van der Heijden YF; Karim F; Mufamadi G; Zako L; Chinappa T; Shepherd BE; Maruri F; Moosa MS; Sterling TR; Pym AS
    Int J Tuberc Lung Dis; 2017 Jun; 21(6):670-676. PubMed ID: 28482962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis.
    Gegia M; Winters N; Benedetti A; van Soolingen D; Menzies D
    Lancet Infect Dis; 2017 Feb; 17(2):223-234. PubMed ID: 27865891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment outcomes for isoniazid-resistant tuberculosis under program conditions in British Columbia, Canada.
    Romanowski K; Chiang LY; Roth DZ; Krajden M; Tang P; Cook VJ; Johnston JC
    BMC Infect Dis; 2017 Sep; 17(1):604. PubMed ID: 28870175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes with Fluoroquinolone-Containing Regimens for Isoniazid-Resistant Pulmonary Tuberculosis.
    Lee H; Jeong BH; Park HY; Jeon K; Huh HJ; Lee NY; Koh WJ
    Antimicrob Agents Chemother; 2016 Jan; 60(1):471-7. PubMed ID: 26525801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of Category I and II regimens in mono- and polyresistant tuberculosis cases in the Philippines.
    Lew WJ; Harrington K; Garfin C; Islam T; Hiatt T; Nishikiori N
    Int J Tuberc Lung Dis; 2016 Feb; 20(2):170-6. PubMed ID: 26792468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
    Kenyon TA; Mwasekaga MJ; Huebner R; Rumisha D; Binkin N; Maganu E
    Int J Tuberc Lung Dis; 1999 Jan; 3(1):4-11. PubMed ID: 10094163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low failure rate in standardised retreatment of tuberculosis in Nicaragua: patient category, drug resistance and survival of 'chronic' patients.
    Heldal E; Arnadottir T; Cruz JR; Tardencilla A; Chacon L
    Int J Tuberc Lung Dis; 2001 Feb; 5(2):129-36. PubMed ID: 11258506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tuberculosis Treatment Outcome and Drug Resistance in Lambaréné, Gabon: A Prospective Cohort Study.
    Bélard S; Remppis J; Bootsma S; Janssen S; Kombila DU; Beyeme JO; Rossatanga EG; Kokou C; Osbak KK; Obiang Mba RM; Kaba HM; Traoré AN; Ehrhardt J; Bache EB; Flamen A; Rüsch-Gerdes S; Frank M; Adegnika AA; Lell B; Niemann S; Kremsner PG; Loembé MM; Alabi AS; Grobusch MP
    Am J Trop Med Hyg; 2016 Aug; 95(2):472-80. PubMed ID: 27352879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting outcomes and drug resistance with standardised treatment of active tuberculosis.
    Oxlade O; Schwartzman K; Pai M; Heymann J; Benedetti A; Royce S; Menzies D
    Eur Respir J; 2010 Oct; 36(4):870-7. PubMed ID: 20351030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
    Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.